Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors

Cytometry Part A

Volumn 79 A, Issue 9, 2011, Pages 684-693

  Diermeier Daucher, Simone ^a   Breindl, Stefanie ^a   Buchholz, Stefan ^a   Ortmann, Olaf ^a   Brockhoff, Gero ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Anti Her2 targeting; BrdU Hoechst quenching; Breast cancer cell lines; Growth factors; Lapatinib; Pertuzumab; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; LAPATINIB; MONOCLONAL ANTIBODY; NEU DIFFERENTIATION FACTOR; PERTUZUMAB; PROTEIN KINASE B; QUINAZOLINE DERIVATIVE; TRASTUZUMAB;

APOPTOSIS; ARTICLE; BREAST TUMOR; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECT; FEMALE; HUMAN; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; NEUREGULIN-1; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 80051869605     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.21107     Document Type: Article

References (42)

1. Pegram MD, Konecny G, Slamon DJ. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (Trastuzumab) therapy for breast cancer. Cancer Treat Res 2000; 103: 57-75.
2. Pegram M, Slamon D. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol 2000; 27: 13-19.
3. Brockhoff G, Heckel B, Schmidt-Bruecken E, Plander M, Hofstaedter F, Vollmann A, Diermeier S. Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation. Cell Prolif 2007; 40: 488-507.
4. Nahta R, Esteva FJ. In vitro effects of Trastuzumab and vinorelbine in Trastuzumab-resistant breast cancer cells. Cancer Chemother Pharmacol 2004; 53: 186-190.
5. Campoli M, Ferris R, Ferrone S, Wang X. Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. Clin Cancer Res 2010; 16: 11-20.
6. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 23: 1073-1078.
7. Brockhoff G, Heiss P, Schlegel J, Hofstaedter F, Knuechel R. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells. Cytometry 2001; 44: 338-348.
8. Diermeier S, Horváth G, Knuechel-Clarke R, Hofstaedter F, Szöllosi J, Brockhoff G. Epidermal growth factor receptor coexpression modulates susceptibility to herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res 2005; 304: 604-619.
9. Barok M, Balazs M, Lazar V, Rakosy Z, Toth E, Treszl A, Vereb G, Colbern GT, Park JW, Szollosi J. Characterization of a novel, Trastuzumab resistant human breast cancer cell line. Front Biosci (Elite Ed) 2010; 2: 627-640.
10. Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, Elenius K, Isola J. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 2004; 3: 1585-1592.
11. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to Trastuzumab in breast cancer. Clin Cancer Res 2009; 15: 7479-7491.
12. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, et al. Activity of the dual kinase inhibitor Lapatinib (GW572016) against HER-2-overexpressing and Trastuzumab-treated breast cancer cells. Cancer Res 2006; 66: 1630-1639.
13. Foster FM, Owens TW, Tanianis-Hughes J, Clarke RB, Brennan K, Bundred NJ, Streuli CH. Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer. Breast Cancer Res 2009; 11: R41.
14. Weigelt B, Lo AT, Park CC, Gray JW, Bissell MJ. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat 2010; 122: 35-43.
15. Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, Smith DJ, Landolfi S, Ramon y Cajal S, Arribas J, et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates Trastuzumab-dependentcell cytotoxicity. Oncogene 2009; 28: 803-814.
16. Giampaglia M, Chiuri VE, Tinelli A, De Laurentiis M, Silvestris N, Lorusso V. Lapatinib in breast cancer: Clinical experiences and future perspectives. Cancer Treat Rev 2010; 36: S72-S79.
17. Macfarlane RJ, Gelmon KA. Lapatinib for breast cancer: A review of the current literature. Expert Opin Drug Saf 2011; 10: 109-121.
18. Badache A, Hynes NE. A new therapeutic antibody masks ErbB2 to its partners. Cancer Cell 2004; 5: 299-301.
19. Diermeier-Daucher S, Hasmann M, Brockhoff G. Flow cytometric FRET analysis of erbB receptor interaction on a cell-by-cell basis. Ann NY Acad Sci 2008; 1130: 280-286.
20. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004; 64: 6652-6659.
21. Reid A, Vidal L, Shaw H, de Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 2007; 43: 481-489.
22. Révillion F, Lhotellier V, Hornez L, Bonneterre J, Peyrat JP. ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol 2008; 19: 73-80.
23. McIntyre E, Blackburn E, Brown PJ, Johnson CG, Gullick WJ. The complete family of epidermal growth factor receptors and their ligands are co-ordinately expressed in breast cancer. Breast Cancer Res Treat 2010; 122: 105-110.
24. Brockhoff G. DNA and proliferation analysis in flow cytometry. In: Sack U, Tárnok A, Rothe G, editors. Cellular Diagnostics-Basic Principles, Methods and Clinical Applications of Flow Cytometry. Freiburg, Germany: Karber; 2008. pp 390-425.
25. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor. GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1: 85-94.
26. Xia W, Gerard CM, Liu L, Baudson NM, Ory TL, Spector NL. Combining Lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 2005; 24: 6213-6221.
27. O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan N, Slamon DJ. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to Trastuzumab but not Lapatinib. Mol Cancer Ther 2010; 9: 1489-1502.
28. Dufner A, Thomas G. Ribosomal S6 kinase signaling and the control of translation. Exp Cell Res 1999; 253: 100-109.
29. Silva CM. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 2004; 23: 8017-8023.
30. Motti ML, De Marco C, Califano D, Fusco A, Viglietto G. Akt-dependent T198 phosphorylation of cyclin-dependent kinase inhibitor p27kip1 in breast cancer. Cell Cycle 2004; 3: 1074-1080.
31. Larrea MD, Wander SA, Slingerland JM. p27 as Jekyll and Hyde: Regulation of cell cycle and cell motility. Cell Cycle 2009; 8: 3455-3461.
32. D'Alessio A, De Luca A, Maiello MR, Lamura L, Rachiglio AM, Napolitano M, Gallo M, Normanno N. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells. Breast Cancer Res Treat 2010; 123: 387-396.
33. Zhu H, Zhang G, Wang Y, Xu N, He S, Zhang W, Chen M, Liu M, Quan L, Bai J, et al. Inhibition of ErbB2 by Herceptin reduces survivin expression via the ErbB2-β-catenin/TCF4-survivin pathway in ErbB2-overexpressed breast cancer cells. Cancer Sci 2010; 101: 1156-1162.
34. Ruchaud S, Carmena M, Earnshaw WC. Chromosomal passengers: Conducting cell division. Nat Rev Mol Cell Biol 2007; 8: 798-812.
35. Stolz A, Ertych N, Bastians H. Tumor suppressor CHK2: Regulator of DNA damage response and mediator of chromosomal stability. Clin Cancer Res 2011; 17: 401-405.
36. Flaherty KT, Puzanov I. Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma. Biochem Pharmacol 2010; 80: 638-646.
37. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989; 9: 1165-1172.
38. Jones JT, Akita RW, Sliwkowski MX. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett 1999; 447: 227-231.
39. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997; 16: 1647-1655.
40. Gaborit N, Larbouret C, Vallaghe J, Peyrusson F, Bascoul-Mollevi C, Crapez E, Azria D, Chardes T, Poul MA, Mathis G, et al. Time resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: A new method to evaluate the efficiency of targeted therapy using monoclonal antibodies. J Biol Chem 2011; 286: 11337-11345.
41. Hughes JB, Berger C, Rødland MS, Hasmann M, Stang E, Madshus IH. Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization. Mol Cancer Ther 2009; 8: 1885-1892.
42. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002; 2: 127-137.